sarscov
new
type
human
coronaviru
identifi
caus
agent
sever
acut
respiratori
syndrom
sar
occas
sar
outbreak
variou
monoclon
antibodi
mab
sarscov
develop
appli
diagnosi
clinic
manag
basic
research
review
overview
biochem
function
properti
applic
sarscov
mab
also
focu
varieti
vaccin
current
develop
discuss
immun
respons
elicit
vaccin
anim
model
hope
better
understand
need
next
fight
newli
emerg
pathogen
futur
outbreak
fatal
sever
acut
respiratori
syndrom
sar
origin
occur
china
subsequ
spread
mani
countri
earli
control
due
concert
worldwid
effort
led
world
health
organis
caus
pathogen
sarscov
identifi
entir
genom
sequenc
quickli
determin
sarscov
belong
distinct
group
known
human
coronavirus
group
group
slightli
pathogen
human
contrari
anim
coronavirus
known
caus
clinic
seriou
diseas
livestock
pet
anim
base
nucleotid
sequenc
homolog
sarscovlik
viru
wild
anim
trade
chines
market
consid
sarscov
emerg
interspeci
transmiss
anim
coronavirus
review
recent
report
strongli
suggest
chines
horsesho
bat
natur
host
sarscov
batsarscov
cage
anim
himalayan
palm
civet
raccoon
dog
amplif
host
sarscov
readili
transmiss
close
contact
famili
member
healthcar
laboratori
worker
sinc
sarscov
infect
replic
respiratori
intestin
tissu
vaccin
elicit
mucos
neutralis
antibodi
particularli
bronchoalveolar
lumen
would
desir
report
high
titr
neutralis
igg
antibodi
sarscov
present
sar
patient
passiv
administr
serum
antibodi
previous
infect
patient
improv
condit
newli
infect
recipi
furthermor
mous
model
passiv
transfer
mous
immun
serum
sarscov
demonstr
reduc
pulmonari
viral
titr
mice
infect
sarscov
result
support
notion
neutralis
antibodi
crucial
protect
sarscov
infect
occas
sar
outbreak
sever
laboratori
endeavour
identifi
monoclon
antibodi
mab
act
sarscov
order
provid
tool
diagnosi
combin
viral
detect
rtpcr
analysi
applic
clinic
treatment
sar
patient
context
overview
biochem
function
properti
sarscov
mab
establish
differ
technic
approach
togeth
applic
utilis
mab
clinic
basic
research
also
discuss
immun
respons
elicit
varieti
vaccin
anim
model
better
understand
requir
develop
effect
vaccin
sarscov
infect
sarscov
encod
four
major
structur
protein
spike
membran
envelop
e
nucleocapsid
n
protein
varieti
mous
human
monoclon
antibodi
mab
recognis
protein
establish
list
tabl
mous
tabl
human
mab
addit
fine
epitopemap
studi
mab
summaris
figur
know
protein
bind
cellular
receptor
recognis
sprotein
amino
acid
residu
region
design
receptor
bind
domain
rbd
thu
protein
especi
rbd
major
target
elicit
neutralis
antibodi
focu
issu
next
section
mous
mab
tabl
whole
virion
use
antigen
establish
mab
frequent
recognis
protein
use
highli
purifi
whole
virion
sarscov
immunis
antigen
inactiv
uvirradi
avoid
unwant
denatur
viru
protein
major
mab
establish
recognis
conform
epitop
protein
virusneutralis
abil
vitro
wherea
mab
recognis
linear
epitop
n
protein
hand
chou
et
al
establish
sever
mab
recognis
linear
epitop
protein
use
detergentdisrupt
virion
antigen
mab
design
high
neutralis
abil
suggest
neutralis
activ
mediat
varieti
antibodi
recognit
site
protein
gubbin
et
al
use
whole
virion
inactiv
propiolacton
obtain
mab
viru
neutralis
abil
surprisingli
major
mab
encod
v
h
gene
famili
v
h
coupl
varieti
light
chain
suggest
correl
neutralis
abil
specif
v
h
gene
allel
anoth
approach
use
recombin
sarscov
protein
immunis
antigen
zhou
et
al
prepar
recombin
protein
fragment
protein
sii
aa
predict
includ
rbd
recombin
protein
fragment
bind
surfac
vero
cell
mab
fragment
potent
vitro
neutralis
abil
et
al
use
small
fragment
recombin
rbd
fuse
human
fc
fragment
rbdfc
immunis
antigen
twentyseven
hybridoma
establish
antigen
specif
map
differ
conformationdepend
adjac
linear
epitop
see
use
recombin
n
protein
che
et
al
isol
antin
mab
use
sensit
antigencaptur
elisa
system
western
blot
consid
clinic
approach
block
sarscov
infect
utilis
neutralis
antibodi
human
mab
establish
differ
techniqu
traggiai
et
al
develop
uniqu
method
ebv
transform
b
cell
enabl
rapid
gener
human
neutralis
antibodi
sarscov
memori
b
cell
pool
recov
sar
patient
effici
immortalis
high
affin
human
mab
success
obtain
case
ebvtransform
b
cell
clone
secret
igg
antibodi
protein
n
protein
like
reflect
actual
memori
b
cell
repertoir
individu
recov
sarscov
infect
sui
et
al
obtain
eight
clone
two
singlechain
variabl
antibodi
fragment
scfv
screen
scfv
librari
construct
nonimmun
human
antibodi
fragment
sarscov
protein
among
clone
bound
protein
rbd
region
show
effici
neutralis
abil
use
similar
approach
van
den
brink
et
al
vitro
neutral
activ
vivo
protect
mous
model
scfv
phage
display
screen
recombin
protein
scfv
clone
etc
memori
b
cell
repertoir
represent
epitop
map
vitro
neutral
vivo
protect
mous
model
corel
sensit
scfv
phage
display
screen
irradi
sarscov
whole
virion
anti
n
epitop
map
immunoelectron
microscopi
ifa
vitro
neutral
scfv
librari
construct
sar
convalesc
patient
select
inactiv
whole
virion
etc
map
protein
potent
neutral
activ
vitro
transgen
mice
human
immunoglobulin
gene
medarex
immun
recombin
protein
clone
epitop
map
vivo
protect
mous
model
scfv
singlechain
variabl
antibodi
fragment
sever
acut
respiratori
syndrom
coronaviru
sever
acut
respiratori
syndrom
coronaviru
obtain
eight
scfv
clone
two
clone
could
map
n
protein
four
protein
one
two
antin
scfv
clone
recognis
linear
epitop
other
recognis
conform
epitop
three
four
anti
scfv
clone
recognis
rbd
retain
vitro
neutralis
activ
duan
et
al
also
utilis
phagedisplay
librari
techniqu
construct
librari
convalesc
sar
patient
one
scfv
clone
recognis
protein
region
potent
neutralis
activ
greenough
et
al
obtain
human
mab
sarscov
structur
protein
immunis
transgen
mice
human
immunoglobulin
gene
one
mab
recognis
rbd
anoth
mab
recognis
region
outsid
rbd
thu
varieti
approach
make
possibl
establish
mab
human
origin
sarscov
interest
techniqu
establish
mab
recov
patient
highaffin
antibodi
potent
biolog
activ
select
viru
elimin
use
infect
establish
antibodi
potent
activ
diagnosi
quit
probabl
clinic
approach
well
epitop
sarscov
protein
spike
protein
sar
patient
sera
recognis
major
conform
linear
protein
epitop
protein
sarscov
genbank
access
residu
long
contain
leader
sequenc
ntermin
figur
protein
divid
two
region
although
cleav
proteas
coronavirus
region
contain
transmembran
cytoplasm
region
contain
rbd
domain
groupi
coronavirus
includ
human
transmiss
gastroenter
viru
tgev
recognis
aminopeptidas
n
cellular
target
molecul
bind
site
map
case
hucov
tgev
groupii
coronavirus
mous
hepat
viru
mhv
recognis
carcinoembryon
antigenrel
cell
adhes
molecul
cellular
receptor
ntermin
residu
contain
receptor
bind
site
upon
bind
target
molecul
protein
undergo
conform
chang
lead
exposur
fusogen
region
part
result
membran
fusion
viral
cellular
membran
mous
mab
recombin
protein
fragment
sii
obtain
zhou
et
al
potent
neutralis
abil
epitop
localis
respect
epitop
howev
slightli
downstream
rbd
shown
wong
et
al
xiao
et
al
hand
among
mab
rbd
fuse
human
fragment
rbdfc
two
mab
recognis
linear
epitop
respect
wherea
remain
mab
recogn
conform
epitop
classifi
six
group
confi
confvi
studi
show
abil
inhibit
bind
sar
pseudoviru
retain
conform
epitop
especi
confiii
iv
v
linear
epitop
likewis
human
mab
protein
recognis
rbd
potent
neutralis
activ
sarscov
discuss
clone
recognis
fragment
context
suggest
import
amino
acid
high
bind
affin
spiga
et
al
tri
model
tertiari
structur
protein
domain
homolog
model
molecular
dynam
method
model
predict
two
hydrophob
pocket
put
receptor
bind
site
model
would
use
evalu
antigen
drift
caus
mutat
region
alreadi
deposit
ncbi
databas
interestingli
yi
et
al
studi
immunogen
protein
mice
dna
immun
singl
amino
acid
substitut
mutat
fail
induc
neutral
antibodi
abolish
viral
entri
mutat
howev
retain
capac
induc
neutral
antibodi
although
also
abolish
viral
entri
thu
singl
amino
acid
mutat
easili
affect
virustocel
interact
therefor
region
ideal
target
structur
neutral
protein
sarscov
highli
basic
structur
protein
amino
acid
n
protein
thought
involv
packag
viral
rnagenom
thu
crucial
viral
replic
pathogenesi
cov
figur
antinprotein
antibodi
gener
found
sera
sar
patient
suggest
nprotein
one
immunodomin
structur
protein
sarscov
addit
sar
patient
sera
recognis
nprotein
larg
number
linear
epitop
least
two
major
conform
epitop
patient
sera
wang
et
al
identifi
peptid
immunogen
epitop
hand
et
al
identifi
two
major
epitop
ctermin
region
middl
region
addit
sever
minor
immunodomin
epitop
also
show
potent
antibodi
respons
elicit
ctermin
region
contain
short
lysinerich
sequenc
ktfpptepkkdkkkktdeaq
howev
function
role
stretch
remain
unknown
van
den
brink
et
al
establish
two
human
antin
scfv
recognis
linear
epitop
rsapritfg
nonlinear
epitop
respect
mice
immunis
inactiv
sarscov
identifi
one
major
epitop
middl
part
recognis
mab
wherea
et
al
identifi
one
major
epitop
adjac
ntermin
region
addit
epitop
ctermin
middl
region
togeth
map
studi
sar
cov
n
protein
suggest
three
major
epitop
localis
ntermin
middl
ctermin
region
respect
respons
potent
immun
respons
human
mice
envelop
e
protein
small
e
protein
residu
long
protein
involv
envelop
morphogenesi
far
know
one
mab
protein
human
e
protein
antibodi
detect
sar
convalesc
patient
sera
confirm
absenc
crossreact
antin
mab
human
coronavirus
elisa
ifa
figur
howev
polyclon
level
report
crossreact
sar
human
coronavirus
wo
et
al
report
falseposit
result
recombin
sarscov
nproteinbas
elisa
assay
mainli
due
presenc
crossreact
sever
acut
respiratori
syndrom
coronaviru
sever
acut
respiratori
syndrom
coronaviru
antibodi
sarscov
nprotein
sera
found
sera
convalesc
patient
respect
contain
antibodi
crossreact
sarscov
nprotein
suggest
presenc
common
epitop
human
cov
nprotein
sera
convalesc
patient
howev
react
sarscov
sprotein
western
blot
analysi
thu
highli
specif
sarscov
mab
requir
sensit
accur
laboratori
diagnosi
neutralis
antibodi
crucial
establish
protect
sarscov
infect
notabl
analysi
memori
b
cell
repertoir
clonal
level
suggest
memori
b
cell
repertoir
recov
sar
patient
bias
toward
neutralis
antibodi
recognis
protein
describ
main
neutralis
protein
epitop
posit
bind
cellular
receptor
rbd
see
figur
therefor
expect
passiv
immunotherapi
utilis
neutralis
antibodi
sarscov
could
promis
therapeut
method
mani
effort
focus
develop
mab
discuss
analysi
rabbit
antisera
recombin
n
protein
suggest
signific
neutralis
abil
anti
antim
antibodi
antin
antibodi
main
neutralis
epitop
protein
rbd
wherea
part
irrelev
bind
site
also
shown
involv
neutralis
presum
via
steric
hindranc
furthermor
competit
neutralis
assay
suggest
presenc
addit
target
site
bind
site
regard
continu
epitop
map
use
phage
display
dodecapeptid
librari
zhong
et
al
report
epitoperich
region
protein
repres
one
major
neutralis
target
sar
patient
block
peptid
correspond
region
human
mab
sarscov
neutralis
activ
attract
reagent
treatment
sar
patient
exampl
ebvtransform
memori
b
cell
recov
sar
patient
specif
protein
neutralis
activ
curious
one
confer
effici
protect
mous
model
sarscov
infect
addit
one
mab
establish
human
scfv
librari
sui
et
al
design
shown
mous
model
display
effect
protect
infect
wildtyp
mutant
virus
isol
patient
furthermor
administ
mice
prophylact
sarscov
replic
reduc
four
order
magnitud
compar
untreat
mice
human
mab
establish
transgen
mice
harbour
human
immunoglobulin
gene
also
neutralis
activ
signific
protect
effect
mous
infect
model
upon
administr
mgkg
dose
togeth
human
mab
could
candid
chemoprophylaxi
therapi
sar
fact
clinic
trial
plan
human
mab
laboratori
diagnosi
sarscov
infect
base
combin
serolog
test
revers
transcriptionpolymeras
chain
reaction
rtpcr
viru
isol
henc
mab
sarscov
structur
protein
establish
sever
group
util
antigencaptur
elisa
immunofluoresc
assay
western
blot
analysi
test
see
tabl
ifa
simplest
serolog
test
detect
pathogen
ifa
sar
diagnosi
carri
use
sever
polyclon
monoclon
antibodi
nprotein
sprotein
irrespect
specif
conform
linear
epitop
show
mab
n
protein
quit
use
diagnosi
term
specif
sensit
et
al
convent
ifa
commerci
sarscov
ifa
kit
western
blot
major
antin
mab
direct
linear
epitop
thu
use
western
blot
detect
kda
band
nprotein
contrast
epitop
nativ
sprotein
mostli
conform
anti
mab
obtain
use
western
blot
howev
use
sdsdenatur
protein
recombin
protein
fragment
immunogen
sever
mab
western
blot
obtain
although
sera
patient
immunis
mice
detect
e
protein
use
mab
detect
either
protein
western
blot
establish
elisa
immunolog
test
presenc
sarscov
virion
patient
specimen
import
complement
rtpcr
test
three
group
far
report
develop
antigen
captur
elisa
system
sarscov
intend
establish
antigencaptur
sandwich
elisa
system
use
total
mous
mab
specif
sand
nprotein
found
viru
protein
load
low
pgml
success
detect
use
antin
mab
captur
antibodi
biotinyl
mab
probe
antibodi
sensit
system
differ
least
four
strain
sarscov
test
contrast
combin
anti
mab
fail
yield
high
titr
che
et
al
utilis
three
mous
antin
mab
captur
antibodi
rabbit
polyclon
antin
antibodi
detect
antibodi
abl
detect
recombin
n
protein
pgml
assay
system
score
posit
approxim
sar
patient
serolog
confirm
healthi
individu
di
et
al
test
serum
sampl
patient
compar
control
sera
healthi
donor
onset
symptom
n
protein
detect
day
sensit
case
patient
posit
neutralis
test
day
nprotein
level
sera
decreas
undetect
beyond
day
specif
assay
calcul
result
serolog
testneg
patient
healthi
donor
report
posit
rate
obtain
sera
day
onset
symptom
neutralisationtest
posit
sar
patient
serolog
confirm
patient
lau
et
al
report
develop
polyclon
antibodybas
elisa
n
protein
utilis
guinea
pig
rabbit
antibodi
recombin
tag
sarscov
nprotein
test
nasopharyng
aspir
urin
faecal
sampl
detect
n
protein
nasopharyng
aspir
sampl
day
onset
diseas
urin
sampl
day
faecal
sampl
day
though
sensit
high
except
day
nasopharyng
aspir
sensit
apart
antigencaptur
detect
system
highthroughput
assay
antisarscov
igg
antibodi
detect
system
detectsar
tm
report
highli
sensit
convalesc
serum
sampl
immunolog
detect
system
would
necessari
compliment
rtpcrbase
diagnosi
futur
improv
detect
system
certainli
contribut
control
sar
pandem
tabl
immun
respons
studi
use
anim
model
includ
macaqu
ferret
cat
golden
syrian
hamster
mice
review
howev
anim
model
show
transient
viral
replic
respiratori
tract
without
manifest
diseas
except
ferret
hamster
ferret
hamster
develop
patholog
disord
lung
infect
ferret
cat
transmit
sarscov
counterpart
hous
togeth
thu
seem
aspect
sarscov
infect
human
reproduc
anim
model
diseas
entiti
quit
differ
exampl
human
rapid
progress
pulmonari
intestin
complic
observ
almost
sar
patient
develop
wateri
diarrhoea
seen
anim
model
despit
differ
outcom
anim
model
still
use
vaccin
develop
evalu
sever
acut
respiratori
syndrom
coronaviru
sever
acut
respiratori
syndrom
coronaviru
antibodi
respons
sar
patient
studi
extens
know
littl
tcell
respons
patient
two
epitop
domain
recognis
memori
cell
sarscovinfect
patient
howev
studi
use
transgen
mice
vitro
prime
pbmc
healthi
donor
identifi
slightli
differ
domin
epitop
domain
mice
epitop
cell
within
domain
current
strategi
elicit
effect
immun
sarscov
list
tabl
know
littl
pathogenesi
sever
acut
respiratori
syndrom
associ
sarscov
infect
live
attenu
sarscov
vaccin
feasibl
candid
sar
vaccin
instead
whole
inactiv
virion
first
choic
mice
subcutan
nasal
inject
whole
virion
inactiv
either
uvirradi
formalin
without
varieti
adjuv
induc
high
level
antibodi
sarscov
surprisingli
observ
uvinactiv
virion
per
se
elicit
consider
high
level
serum
iggtyp
neutralis
antibodi
without
alum
adjuv
furthermor
level
serum
igg
antibodi
retain
peak
month
singl
inject
probabl
reflect
gener
mainten
longterm
afc
antibodyform
cell
ie
effector
memori
cell
iga
respons
elicit
mucos
tissu
subcutan
inject
wherea
respons
elicit
mice
immunis
nasal
inactiv
virion
aid
potent
mucos
adjuv
cholera
toxin
ct
cpg
chines
govern
recent
announc
complet
phase
studi
inactiv
virion
vaccin
seriou
complic
observ
far
http
mytdctrad
comairnewseindexasp
id
viru
vectorbas
vaccin
describ
previou
section
n
protein
two
major
viral
protein
induc
high
level
antibodi
respons
current
strategi
develop
effect
vaccin
gener
reli
induct
potent
neutralis
antibodi
mucos
surfac
studi
attenu
parainfluenza
viru
suggest
immunis
recombin
protein
e
n
protein
result
protect
elicit
neutralis
antibodi
indic
advantag
antigenexpress
vaccin
current
develop
likewis
modifi
vaccinia
viru
ankara
mva
express
protein
mva
use
success
mice
rabbit
monkey
mva
vaccin
induc
high
level
neutralis
antibodi
turn
result
protect
monkey
viru
infect
contrast
inocul
attenu
vaccinia
express
protein
ferret
effect
viral
load
caus
hepat
upon
challeng
sarscov
mvasimmunis
ferret
howev
remain
unknown
whether
caus
mechan
antibodydepend
enhanc
viru
infect
immunopatholog
effect
liver
felin
coronaviru
infect
antibodydepend
enhanc
diseas
observ
vaccin
anim
vaccinia
vector
thu
unfavour
side
effect
mva
vaccin
care
consid
applic
adenoviru
type
vector
express
codonoptimis
n
also
develop
one
candid
vaccin
six
monkey
immunis
three
recombin
adenovirus
develop
antibodi
fragment
neutralis
activ
also
develop
variou
level
ifn
produc
cell
reactiv
pool
n
peptid
howev
challeng
experi
carri
whether
preexist
immun
adenoviru
reduc
efficaci
recombin
adenoviru
vaccin
human
need
investig
rhabdovirusbas
vaccin
also
develop
use
recombin
technolog
rabi
viru
rv
vesicular
stomat
viru
vsv
virus
encod
protein
genom
induc
high
level
neutralis
antibodi
singl
inject
mice
case
vsvbase
vector
preexist
immun
concern
mice
protect
sarscov
infect
intranas
immunis
rv
replic
mucos
membran
cell
one
advantag
suggest
protein
may
modifi
glycosyl
replic
rv
case
protect
abil
rvbase
vaccin
need
test
dna
vaccin
dna
immunis
develop
safe
stabl
vaccin
technolog
protect
varieti
infecti
diseas
sinc
mani
effort
made
improv
effici
dna
vaccin
exampl
ad
cytokin
costimulatori
dna
adjuv
review
use
modifi
codon
optimis
express
yang
et
al
prepar
plasmid
encod
protein
analys
abil
elicit
antivir
immun
mice
cell
reactiv
overlap
peptid
detect
mice
gener
neutralis
antibodi
account
protect
respiratori
infect
deplet
cell
adopt
tcell
transfer
immunis
cell
affect
protect
immun
wherea
passiv
transfer
igg
immunis
mice
provid
immun
protect
studi
along
attenu
parainfluenza
viru
indic
humor
immun
protein
alon
confer
protect
howev
sinc
sarscov
replic
mice
transient
remain
elucid
whether
tcell
immun
also
import
especi
neutralis
antibodi
fail
clear
viru
studi
use
plasmidexpress
n
protein
expect
high
level
intracellular
n
protein
express
may
induc
strong
ctl
respons
order
increas
effici
kim
et
al
link
calreticulin
crt
gene
n
gene
ca
bind
heat
shock
famili
protein
abundantli
present
endoplasm
reticulum
mice
inject
three
time
crtn
dna
gene
gun
humor
tcell
immun
respons
enhanc
immunis
mice
protect
infect
recombin
vaccinia
express
n
protein
approach
far
demonstr
protect
role
nreactiv
cell
vaccin
howev
remain
unknown
whether
nreactiv
cell
contribut
suppress
progress
sar
natur
infect
lastli
combin
dna
vaccin
recombin
protein
wholekil
viru
design
expect
regimen
may
enhanc
titr
neutralis
antibodi
also
tcell
respons
though
import
latter
protect
yet
clear
recombin
protein
vaccin
protein
sarscov
heavili
glycosyl
hiv
larg
scale
product
recombin
protein
econom
difficult
nevertheless
compon
vaccin
great
advantag
respect
safeti
effect
enough
baculoviru
system
develop
bisht
et
al
produc
solubl
recombin
polypeptid
contain
ntermin
segment
spike
glycoprotein
ns
mice
inject
subcutan
three
time
ns
ribi
mpl
tdm
adjuv
protect
sarscov
infect
week
later
would
interest
studi
whether
neutralis
antibodi
elicit
protein
subunit
vaccin
sustain
abl
protect
suscept
anim
diseas
mab
structur
protein
sarscov
rapidli
establish
appli
basic
research
also
clinic
practic
includ
sar
patient
therapi
studi
utilis
antibodi
provid
us
enorm
inform
respect
immun
respons
elicit
sarscov
develop
vaccin
sarscov
learn
emerg
sar
potent
use
prepar
futur
outbreak
new
pathogen
like
come
wild
anim
